--- title: "U.S. stock market midday update: YD Bio down 14.13% with increased volume and sharp decline, no major negative news, intensified capital speculation causing volatility" type: "News" locale: "en" url: "https://longbridge.com/en/news/288761225.md" description: "YD Bio fell 14.13%; AbbVie rose 2.85%, with a transaction volume of USD 882 million; Gilead Sciences rose 0.40%, with a transaction volume of USD 613 million; Amgen rose 2.05%, with a transaction volume of USD 591 million; Vertex Pharmaceuticals rose 4.27%, with a market value of USD 113.4 billion" datetime: "2026-06-04T18:48:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288761225.md) - [en](https://longbridge.com/en/news/288761225.md) - [zh-HK](https://longbridge.com/zh-HK/news/288761225.md) --- # U.S. stock market midday update: YD Bio down 14.13% with increased volume and sharp decline, no major negative news, intensified capital speculation causing volatility **U.S. Stock Market Midday Update** YD Bio, down 14.13%, with increased trading volume, no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** AbbVie up 2.85%, with increased trading volume. Based on recent key news: 1. On June 3, AbbVie announced its participation in the Goldman Sachs Global Healthcare Conference, showcasing its progress in oncology, including next-generation antibody-drug conjugates and T-cell engagers, boosting market confidence. 2. On June 2, AbbVie received EU approval for its drug AQUIPTA for the acute treatment and prevention of migraine in adults, supporting its expansion in the European market. 3. On June 2, AbbVie reached an agreement with Rongchang Biologics to acquire global rights to a novel PD-1/VEGF bispecific antibody, further enhancing its R&D pipeline. The pharmaceutical industry is active in innovative drug development, attracting high market attention. Gilead Sciences up 0.40%. Based on recent key news: 1. On June 1, Gilead Sciences Chairman and CEO Daniel O’Day sold 15,000 shares of common stock, reducing his direct holdings to 617,567 shares. This move may raise market concerns about confidence in the company's leadership, affecting the stock price. 2. On June 2, Gilead Sciences announced the latest research results for its Livdelzi in treating primary biliary cholangitis (PBC), showing that the drug significantly improved the normalization rate of key liver marker ALP over 52 weeks, with good safety. This positive result boosted market confidence in the company's product line. 3. On May 22, Gilead Sciences' Hepcludex injection received FDA approval for the treatment of adult patients with chronic hepatitis B virus infection, marking it as the first FDA-approved treatment for chronic HDV infection, further solidifying the company's leading position in liver disease treatment. The biotechnology industry has performed strongly recently, with an increase in the number of new drug approvals by the FDA. Amgen up 2.05%, with increased trading volume. Based on recent key news: 1. On June 3, Amgen's anti-tumor drug Imdylltra received EU market authorization for the treatment of small cell lung cancer patients. This approval is based on the results of the DeLLphi-304 trial, showing a 40% reduction in the risk of death compared to chemotherapy, positively impacting the stock price. 2. On June 4, Amgen announced that its key products and strong pipeline progress in the fields of obesity and oncology drove robust first-quarter growth. The application of AI technology in R&D, manufacturing, and commercial operations has improved efficiency and revenue growth, further boosting market confidence. 3. On June 3, the usage restrictions for Amgen's rare disease drug Tavneos in Japan were lifted, allowing new patients to use it. Despite previous concerns due to 20 reported deaths, ongoing regulatory monitoring and safety assessments have instilled confidence in the market Balancing Innovation and Safety in the Biopharmaceutical Industry. **Stocks Ranked Among the Top in Market Capitalization in the Industry** Futai Pharmaceutical rose by 4.27%, with increased trading volume. There have been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news ### Related Stocks - [YDES.US](https://longbridge.com/en/quote/YDES.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [GILD.US](https://longbridge.com/en/quote/GILD.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Biogen to acquire RayThera for up to $1bn](https://longbridge.com/en/news/290280646.md) - [Stealth BioTherapeutics removes cloak to become Mighty](https://longbridge.com/en/news/289923024.md) - [Certara Rated Buy as Peer Deal Underscores Discounted Valuation and Supports Long-Term Growth Upside](https://longbridge.com/en/news/289936357.md) - [TrialAssure and Cancer Research UK Collaborate to Advance AI-Supported Regulatory Document Authoring](https://longbridge.com/en/news/290203206.md) - [Edgewise Therapeutics Reports Improvements In Heart Drug Trial](https://longbridge.com/en/news/289953221.md)